SciClone Pharma launches $281m Hong Kong IPO

Jonathan Breen

February 19, 2021 06:00 am

SciClone Pharmaceuticals, which manufactures a possible treatment for the coronavirus, hit the IPO market with a HK$2.18bn ($281.2m) offering on Friday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Nomura Credit Suisse Equity IPOs Health and Biotech Equity China China International Capital Corp Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia